No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
RVNC240621C2500
- 0.35
- 0.000.00%
15min DelayClose Jun 18 16:00 ET
0.35High0.35Low
0.35Open0.35Pre Close1 Volume126 Open Interest2.50Strike Price35.00Turnover209.95%IV1.79%PremiumJun 21, 2024Expiry Date0.30Intrinsic Value100Multiplier1DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.8006Delta0.6766Gamma8.00Leverage Ratio-0.0337Theta0.0001Rho6.40Eff Leverage0.0005Vega
Intraday
- 5D
- Daily
News
Revance to Participate in Upcoming Investor Conferences
Revance Therapeutics, Inc. (NASDAQ:RVNC) today announced that the company will be participating in the following investor conferences. William Blair 44th Annual Growth Stock Conference Chief Financial Officer Tobin
Revance Therapeutics Price Target Cut to $11.00/Share From $12.00 by HC Wainwright & Co.
Revance Therapeutics Price Target Cut to $11.00/Share From $12.00 by HC Wainwright & Co.
Revance Therapeutics Is Maintained at Neutral by Goldman Sachs
Revance Therapeutics Is Maintained at Neutral by Goldman Sachs
Express News | Goldman Sachs Maintains Neutral on Revance Therapeutics, Lowers Price Target to $8
Barclays Sticks to Its Buy Rating for Revance Therapeutics (RVNC)
Revance Therapeutics Reports Q1 2024 Financial Results: Revenue Growth Amidst Rising Operating ...
Comments
$Revance Therapeutics(RVNC.US$ nice bounce
Despite strong revenue growth, the significant share price drop indicates potential unresolved company challenges. It's advised to scrutinize the stock and forecasts before purchase.
$Revance Therapeutics(RVNC.US$ Monday showed sales volumn rose 22% in Q3, reflecting positive feedback on the product's performance profile and the new pricing strategy. The firm predicted an unaudited Q4 and full-year 2023 revenue between $58 million and $59 million and $212 million and $213 million, representing approximately 28% and 80% YoY growth, respectively.
1
Concerns raised by insiders' stock selling. CEO Mark Foley's sale was price-wise favorable. Despite no recent insider purchase, the 1.9% insider stake suggests alignment with shareholders.
Read more